Nothing Special   »   [go: up one dir, main page]

WO2012103279A2 - Methods and compositions for the synthesis of multimerizing agents - Google Patents

Methods and compositions for the synthesis of multimerizing agents Download PDF

Info

Publication number
WO2012103279A2
WO2012103279A2 PCT/US2012/022642 US2012022642W WO2012103279A2 WO 2012103279 A2 WO2012103279 A2 WO 2012103279A2 US 2012022642 W US2012022642 W US 2012022642W WO 2012103279 A2 WO2012103279 A2 WO 2012103279A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
producing
dimethylaminomethyl
diaminopropane
produce
Prior art date
Application number
PCT/US2012/022642
Other languages
French (fr)
Other versions
WO2012103279A3 (en
Inventor
Feng Li
Yihan Wang
Original Assignee
Ariad Pharmaceuticals, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals, Incorporated filed Critical Ariad Pharmaceuticals, Incorporated
Priority to US13/981,051 priority Critical patent/US9024028B2/en
Priority to AU2012209103A priority patent/AU2012209103B2/en
Publication of WO2012103279A2 publication Critical patent/WO2012103279A2/en
Publication of WO2012103279A3 publication Critical patent/WO2012103279A3/en
Priority to US14/607,831 priority patent/US9573934B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/06Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms
    • C07C209/08Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/74Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/16Preparation of optical isomers
    • C07C231/18Preparation of optical isomers by stereospecific synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/06Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the present invention relates to methods and compositions for the synthesis of multimerizing agents.
  • AP20187 is a small organic compound [CAS Registry No. 195 5 14-80-8, molecular weight 1482.7 5 ] that induces controlled biological processes within cells having appropriate genetic alterations.
  • AP20187 and related compounds provide a means for regulating genetically modified cells on the principle that intracellular signaling mechanisms can be regulated by specific protein-protein interactions. By selecting protein interactions that produce a desired cellular response and engineering those proteins to interact only in the presence of a small-molecule multimerizing agent, such as AP20187, it is possible to bring complex biological processes under direct control.
  • AP20187 can be used to regulate the production of therapeutic proteins and to control signal transduction in genetically altered cells to control cell death, proliferation, immune function, etc.
  • the broad utility of AP20187 and other multimerizers has led to a significant body of scientific publications involving a range of biological contexts.
  • AP20187 includes multiple stereocenters.
  • the configuration at each of the stereocenters has been found to be important to the biological activity of the compound. That structural complexity and chirality is also an important consideration in the production of the compounds. While methods and materials for the synthesis of AP20187, and related compounds, are disclosed in US Patent No. 6,150,527, new methods and intermediates which lend themselves to greater product purity and to greater overall efficiency, convenience, economics and/or scalability are particularly desirable.
  • the invention features methods and compositions for the synthesis of multimerizing agents.
  • the invention features the compound:
  • the invention features the compound:
  • the invention features the quaternary salt of 3-bromo-2-bromomethyl-N,N-dimethylpropylamine in solid form and described by the formula:
  • the invention also features the solid crystalline quaternary salt form of 3-bromo-2-bromomethyl-
  • the invention features the compound AP22895 [CAS Registry No. 2471 18-51-0], having the formula:
  • the invention features a method for the chiral synthesis of the compound, API 73 6 0, the method including: (a) reacting the compound AP22895 with ethyl iodide in the presence of a base to form compound X:
  • the base is lithium bis(trimethylsilyl)amide.
  • the invention features a method for producing dimethyl amide 3 by treating the corresponding ethyl ester with dimethylamine in the presence of base:
  • the invention features a method for producing compound 4 by providing the corresponding amide 3 and treating it with a reducing agent to produce compound 4:
  • the reducing agent is L1AIH4.
  • the invention features a method for producing 2-N,N-dimethylaminomethyl-l,3-diaminopropane (compound 6) , the method including:
  • the invention features a method for producing 2-N,N-dimethylaminomethyl-l,3-diaminopropane (compound 6) , the method including providing the quaternary salt :
  • the method including: (a) dissolving a composition including the carboxylic acid, AP20792, of the formula:
  • the method further includes the step of producing 2-N,N-dimethylaminomethyl-l,3-diaminopropane from a quaternary salt as described herein, or from compound 4 as described herein.
  • the invention features a method for producing AP20187, having the formula:
  • the method including coupling the dimeric alcohol, AP20793, with the carboxylic acid, AP20792, having the formula:
  • the invention features a method for producing AP20187 by : (a) coupling 2-N,N- dimethylaminomethyl-l,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (b) coupling the AP20793 so produced with AP17362 to yield AP20187.
  • the method further includes the step of producing AP17362 by coupling AP17360 with methyl-L-pipecolic acid, or a salt thereof.
  • the invention features a method for producing AP20187 by: (a) reacting 3-bromo-2- bromomethyl-N,N-dimethylpropylamine or the quaternary salt thereof with diformylamine to produce 2- N,N-dimethylaminomethyl-l,3-diaminopropane; (b) coupling 2-N,N-dimethylaminomethy 1-1,3 - diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (c) coupling the AP20793 so produced with AP17362 to yield AP20187.
  • the method further includes the step of producing AP17362 by coupling AP17360 with methyl-L-pipecolic acid, or a salt thereof.
  • the method can further include recovering the compound so produced, or a salt thereof, from the reaction mixture.
  • the method can include activating an acid with an activating agent selected from DCC, DIPCDI, DIEA, BOP, PyBOP, HBTU, TBTU, HOBt and any other coupling reagents used in the preparation of coupling of carboxylic acids with alcohols or amines to form esters and amides, respectively, examples of which agents are disclosed herein.
  • an activating agent selected from DCC, DIPCDI, DIEA, BOP, PyBOP, HBTU, TBTU, HOBt and any other coupling reagents used in the preparation of coupling of carboxylic acids with alcohols or amines to form esters and amides, respectively, examples of which agents are disclosed herein.
  • the reagents and/or products of the reaction may be substantially pure.
  • AP20187 refers to the compound depicted below and pharmaceutically acceptable salts thereof.
  • AP20793 refers to the compound depicted below and pharmaceutically acce table salts thereof.
  • substantially pure refers to compositions containing a compound of interest, such as diastereomeric impurity, in which the compound of interest is present in the composition in a diastereomeric excess of from 5 0% to 100%, 60% to 99.9%, 75% to 99.9%, 50% to 99%, 50% to 98%, 80% to 100%, 90% to 100%, or from 94% to 99.8%.
  • Substantially pure compositions can be prepared and analyzed using the chromatographic methods described herein.
  • Substantially pure compositions can include non isomeric impurities (i.e., solvents, salts, and reaction side products).
  • AP17362 is produced in high purity via steps 6-8 (see Examples lf-lh). Some remaining impurities may readily be removed by crystallization of AP17362.
  • Coupling of N-acyl amino acids with alcohols via a DCC mediated intermediate causes low levels of racemization to the alpha position of the carboxylic acid component (AP17362, carbon 2/2').
  • the extent of racemization is controlled by reaction conditions and results in the formation of AP20187 diastereomers.
  • Example 1 Synthesis of AP20187.
  • Pd/C 80.0 g, 5 wt%) was charged into a 5 L reactor containing MeOH (600 mL). Ammonium formate (132.4 g, 2.10 moles) was then charged into the reactor and magnetic agitation commenced. AP14894 (400 g, 1.41 moles) in MeOH (1000 mL) was then charged to the reactor. The reactor was equipped with a nitrogen purge and reflux condenser. The reaction mixture was heated at reflux ( 55 °C) for 3.5 hours after which time TLC analysis indicated all starting material had been consumed. The reaction mixture was then filtered and the filter cake washed with hot MeOH (1100 mL). The filtrate was then heated to 50 °C and water (2750 mL) added.
  • the crude product (439 g) was recrystallized by dissolving in MeOH (2175 mL), heating to reflux, and adding water till a cloudy point was observed. Reheating the solution to boil, followed by slow cooling, results in a precipitate which was filtered, dried under vacuum for 2 hours, and was placed in a vacuum oven at 40 °C overnight.
  • the product was recrystallized in the following manner: AP20792 (341.3 g) was suspended in EtOAc (900 mL) and heated at reflux for 2.5 hours with agitation and filtered while hot. The filtercake was weighed (6 g, -1.8%). The filtrate was reheated to boil for 2 hours then seeded with material of 99. 5 % ee and the solution allowed to cool to room temperature with agitation.
  • the resulting cream colored colloidal solution was treated at -25 * C with ethyl iodide (424 mL, 5 .30 moles) via cannula over a 1 hour period. (A heat kick of ⁇ 5 °C may be observed for the initial addition of 50 mL of ethyl iodide. If this occurs, the temperature was adjusted to - 25 "C and ethyl iodide addition continued.) The solution was allowed to stir at -25 ° C for 2 hours as the colloidal solution slowly changes to a homogeneous brown solution. The brown solution was then allowed to warm to room temperature and stirred overnight.
  • AP14900 5 00 g, 1.97 moles
  • (-)-cinchonidine 580 g, 1.97 moles
  • Acetonitrile 7500 mL
  • the homogeneous solution was allowed to cool to room temperature with concomitant formation of salts.
  • the solids were then filtered and the crystallization procedure was carried out an additional five times utilizing acetonitrile (7000, 7000, 6500, 6500, and 5000 mL) as solvent.
  • the diastereomeric salt was then suspended in water (1400 mL) and dichloromethane (600 mL) and the solution was agitated until all salt was dissolved.
  • the agitated mixture was adjusted to pH 2 by the addition of concentrated HCl, the organic layer was separated and the aqueous layer extracted with a further amount of CH 2 C1 2 (2 300 mL).
  • the combined organic layers were then washed with a 1 N HCl solution (2 200 mL) to remove any remaining (-)-cinchonidine. These acid washings were then reextracted with CH 2 C1 2 (100 mL) and all CH 2 C1 2 solutions were combined.
  • the combined organic solutions were washed with a 10% aqueous NaHC03 solution (200 mL), dried over anhydrous MgS04, concentrated on a rotary evaporator to a volume of -250 mL, and then hexane was added (500 mL).
  • Example 2 Chiral synthesis of (S)-2-(3,4,5-Trimethoxyphenyl)butyric acid (AP17360).
  • a chiral synthesis for AP17360 was developed to reduce the level of diastereomeric impurities present in AP1903 and AP20187.
  • linker 2-N,N-dimethylaminomethyl-l,3-diaminopropane was synthesized for use as an intermediate in the synthesis of AP20187 as outlined in the synthetic scheme below. j» «**s CIV"", 1)NtN ⁇ CHOP OWM*
  • the solution was extracted with ethyl acetate (4 ⁇ 1 L, pH adjusted to 2.5 following each extraction). The combined organics were dried and evaporated to a colorless oil. After the addition of 1.35 L of pyridine, the solution was stirred at 90 °C overnight (16 hours). The solution was distilled at 80 °C (ca. 150 mmHg) to remove the pyridine, and the product was removed by distillation at 55-65 °C (1-2 mmHg), 261.7 g, in 69% yield.
  • step 4(a) While diethyl bis(hydroxymethyl) malonate was used in step 4(a) to make the diethyl compound that was converted into compound 2, other aliphatic or aromatic malonate esters esters could also be used to generate the analogous aliphatic or aromatic ester of compound 2, which is subsquently converted into an amide and reduced as described below.
  • L1ALH4 (37.7 g) was suspended in 1.8 L of anhydrous THF under nitrogen at room temperature and stirred for 5 minutes. To this suspension was then dropped in a solution of 3 (169 g, 0.903 mol) in 1 L of anhydrous THF, keeping the inner temperature lower than 25 °C. The mixture was refluxed for 4 hours. After cooling to room temperature, the reaction was quenched with 600 mL of pre-cooled water, keeping the inner temperature lower than 3 °C. 1.5 L of CH 2 CL 2 was added with stirring. The top clear solution was decanted. The remainder was placed into a separatory funnel, and the clear solution was drained slowly. The solid was washed with CH2CI2 twice. The organics were washed with brine, dried, and evaporated to a light yellow oil, 149 g, in 95% yield.
  • the dibromide salt 5 ( 5 8. 5 g, 0.172 mol) was stirred in 410 mL of water and 5 40 mL of saturated Na 2 C0 3 for 5 minutes and 1 L of CH 2 C1 2 was added. After stirring for another 5 minutes, the layers were separated. The aqueous layer was extracted with CH2CI2 (4 ⁇ 600 mL). The organics were dried over Na 2 C0 3 twice and evaporated to produce a solid (32 g). The solid was suspended in 1325 mL of anhydrous acetonitrile and sodium diformylamine (24.53 g, 0.258 mol) was added. The reaction was stirred at 100 °C overnight. After cooling to room temperature, the solid was filtered out and the filtrate was evaporated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention features methods and compositions for the synthesis of multimerizing agents.

Description

Methods and Compositions for the Synthesis of Mnltimerizing Agents
Background of the Invention
The present invention relates to methods and compositions for the synthesis of multimerizing agents.
AP20187 is a small organic compound [CAS Registry No. 195514-80-8, molecular weight 1482.75] that induces controlled biological processes within cells having appropriate genetic alterations. AP20187 and related compounds provide a means for regulating genetically modified cells on the principle that intracellular signaling mechanisms can be regulated by specific protein-protein interactions. By selecting protein interactions that produce a desired cellular response and engineering those proteins to interact only in the presence of a small-molecule multimerizing agent, such as AP20187, it is possible to bring complex biological processes under direct control. For example, AP20187 can be used to regulate the production of therapeutic proteins and to control signal transduction in genetically altered cells to control cell death, proliferation, immune function, etc. The broad utility of AP20187 and other multimerizers has led to a significant body of scientific publications involving a range of biological contexts.
AP20187 includes multiple stereocenters. The configuration at each of the stereocenters has been found to be important to the biological activity of the compound. That structural complexity and chirality is also an important consideration in the production of the compounds. While methods and materials for the synthesis of AP20187, and related compounds, are disclosed in US Patent No. 6,150,527, new methods and intermediates which lend themselves to greater product purity and to greater overall efficiency, convenience, economics and/or scalability are particularly desirable.
Summary of the Invention
The invention features methods and compositions for the synthesis of multimerizing agents. The invention features the compound:
Figure imgf000002_0001
The invention features the compound:
Figure imgf000003_0001
, or a salt thereof.
The invention features the quaternary salt of 3-bromo-2-bromomethyl-N,N-dimethylpropylamine in solid form and described by the formula:
Figure imgf000003_0002
The invention also features the solid crystalline quaternary salt form of 3-bromo-2-bromomethyl-
Ν,Ν-dimethylpropylamine described by the formula:
Figure imgf000003_0003
The invention features the compound AP22895 [CAS Registry No. 2471 18-51-0], having the formula:
Figure imgf000003_0004
The invention features a method for the chiral synthesis of the compound, API 7360, the method including: (a) reacting the compound AP22895 with ethyl iodide in the presence of a base to form compound X:
Figure imgf000003_0005
Figure imgf000004_0001
In particular embodiments, the base is lithium bis(trimethylsilyl)amide.
The invention features a method for producing dimethyl amide 3 by treating the corresponding ethyl ester with dimethylamine in the presence of base:
° (Me)2NH ° ΝΜΘ2 o^ -o base o^o
3
to form the desired dimethyl amide.
The invention features a method for producing compound 4 by providing the corresponding amide 3 and treating it with a reducing agent to produce compound 4:
Figure imgf000004_0002
3 4
In certain embodiments, the reducing agent is L1AIH4.
The invention features a method for producing 2-N,N-dimethylaminomethyl-l,3-diaminopropane (compound 6) , the method including:
Figure imgf000004_0003
(a) reacting compound 4 with HBr to form 3-bromo-2-bromomethyl-N,N-dimethylpropylamine; and
(b) reacting the 3-bromo-2-bromomethyl-N,N-dimethylpropylamine with diformylamine to produce 2-N,N-dimethylaminomethy]-l,3-diaminopropane.
The invention features a method for producing 2-N,N-dimethylaminomethyl-l,3-diaminopropane (compound 6) , the method including providing the quaternary salt :
Figure imgf000005_0001
and reacting it with diformylamine to produce 2-N,N-dimethylaminomethyl-l,3-diaminopropane.
The in
Figure imgf000005_0002
AP20793
the method including: (a) dissolving a composition including the carboxylic acid, AP20792, of the formula:
Figure imgf000005_0003
in a solvent; (b) treating the resulting solution with a carboxyl activating agent to form activated AP20792; and (c) reacting the activated AP20792 with a composition including 2-N,N- dimethylaminomethyl-l,3-diaminopropane to form a mixture including AP20793. In some embodiments, the method further includes the step of producing 2-N,N-dimethylaminomethyl-l,3-diaminopropane from a quaternary salt as described herein, or from compound 4 as described herein.
The invention features a method for producing AP20187, having the formula:
Figure imgf000005_0004
the method including coupling the dimeric alcohol, AP20793, with the carboxylic acid, AP20792, having the formula:
Figure imgf000006_0001
to yield AP20187.
The invention features a method for producing AP20187 by : (a) coupling 2-N,N- dimethylaminomethyl-l,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (b) coupling the AP20793 so produced with AP17362 to yield AP20187. In particular embodiments, the method further includes the step of producing AP17362 by coupling AP17360 with methyl-L-pipecolic acid, or a salt thereof.
The invention features a method for producing AP20187 by: (a) reacting 3-bromo-2- bromomethyl-N,N-dimethylpropylamine or the quaternary salt thereof with diformylamine to produce 2- N,N-dimethylaminomethyl-l,3-diaminopropane; (b) coupling 2-N,N-dimethylaminomethy 1-1,3 - diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (c) coupling the AP20793 so produced with AP17362 to yield AP20187. In particular embodiments, the method further includes the step of producing AP17362 by coupling AP17360 with methyl-L-pipecolic acid, or a salt thereof.
In any of the above methods, the method can further include recovering the compound so produced, or a salt thereof, from the reaction mixture.
In any of the above methods, the method can include activating an acid with an activating agent selected from DCC, DIPCDI, DIEA, BOP, PyBOP, HBTU, TBTU, HOBt and any other coupling reagents used in the preparation of coupling of carboxylic acids with alcohols or amines to form esters and amides, respectively, examples of which agents are disclosed herein. In any of the above methods, the reagents and/or products of the reaction may be substantially pure.
As used herein, the term "AP20187" refers to the compound depicted below and pharmaceutically acceptable salts thereof.
Figure imgf000006_0002
As used herein, the term "AP20793" refers to the compound depicted below and pharmaceutically acce table salts thereof.
Figure imgf000007_0001
As used herein, "substantially pure" refers to compositions containing a compound of interest, such as diastereomeric impurity, in which the compound of interest is present in the composition in a diastereomeric excess of from 50% to 100%, 60% to 99.9%, 75% to 99.9%, 50% to 99%, 50% to 98%, 80% to 100%, 90% to 100%, or from 94% to 99.8%. Substantially pure compositions can be prepared and analyzed using the chromatographic methods described herein. Substantially pure compositions can include non isomeric impurities (i.e., solvents, salts, and reaction side products).
Other features and advantages of the invention will be apparent from the following detailed description and the claims.
Detailed Description
We have discovered improved methods for synthesizing AP20187. These improvements contribute to the isomeric purity of the products, and to the overall efficiency and scalability of production. Of particular interest, as disclosed herein, one can avoid or reduce the level of impurities in the final product. Such impurities can frustrate even expensive and inconvenient purification procedures and can lead to a poorly performing reagent.
The "bottom half of AP20187 is formed from AP17362. AP17362 is produced in high purity via steps 6-8 (see Examples lf-lh). Some remaining impurities may readily be removed by crystallization of AP17362.
In an alternative synthetic approach, a chiral synthesis of AP17360 is utilized (as described in Example 3) to further reduce the introduction the isomeric impurity (R)-2-(3,4,5- Trimethoxyphenyl)butyric acid.
Coupling of N-acyl amino acids with alcohols via a DCC mediated intermediate (such as that used in step 9 (see Example 1 i)) causes low levels of racemization to the alpha position of the carboxylic acid component (AP17362, carbon 2/2'). The extent of racemization is controlled by reaction conditions and results in the formation of AP20187 diastereomers.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the methods and compounds claimed herein are performed, made, and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Example 1: Synthesis of AP20187.
AP20187 was prepared using standard organic chemical synthetic methodology in a convergent multistep process. (la) Step 1. Synthesis of (E)-3-(3,4-Dimethoxyphenyl)-l-(3-hydroxyphenyl)-2-propen-l-one
(API 4894).
Figure imgf000008_0001
AP17380 AP17381 AP14894
[178445-80-2] A solution of 3,4-dimethoxybenzaldehyde AP17380 (400 g, 2.41 moles) and
3'-hydroxyacetophenone AP17381 (328 g, 2.41 moles) in EtOH (3200 mL) was treated with a solution of aqueous KOH (536 g, 1200 mL) over a 1 hour period. The resulting solution was allowed to stir for 16 h at room temperature. The reaction mixture was then treated with EtOH (2000 mL) followed by water (1200 mL). A solution of EtOH/water (3400 mL, 1 : 1) was then added and the reaction mixture acidified to pH 6 using concentrated HCl (720 mL). After addition of acid, water (4000 mL) was added to induce precipitation. The resulting mixture was left stirring overnight and the solids then filtered, washed with water (2 χ 900 mL) and then hexane (2 χ 800 mL). The product was dried under vacuum for 3 hours and then placed in a vacuum oven at
50 °C for 6 days to provide AP14894 (609 g, 89%) as a yellow solid: mp 138-139 °C; TLC
(EtOAc/hexane, 1 :1 ) Rf = 0.35; Ή NMR (DMSO-d6, 300 MHz) 9.85 (br s, 1H), 7.71 (d, J= 6.6 Hz, 2H), 7.61 (d, J= 7.7 Hz, 1H), 7.53 (d, J= 1.7 Hz, 1H), 7.47 (d, J= 1.7 Hz, 1H), 7.39-7.34 (m, 2H), 7.07-7.00 (m, 2H), 3.87 (s, 3H), 3.82 (s, 3H) ; 13C NMR (DMSO-d6, 75 MHz) 189.4, 158.2, 151.6, 149.4, 144.7, 139.7, 130.1, 127.9, 124.2, 120.4, 120.2, 119.7, 1 15.0, 112.0, 1 1 1.2, 56.1, 56.0; LRMS (ES+) (M+H)+ 285; Anal. Calcd for C17H1604: C, 71.82; H, 5.67. Found: C, 71.55; H, 5.61.
(lb) Step 2. Synthesis of (3-(3,4-Dimethoxyphenyl)-l-(3-hydroxyphenyl)-l-propanone (API 4895).
Figure imgf000009_0001
AP14894 AP14895
[178445-80-2] [178445-83-5]
Pd/C (80.0 g, 5 wt%) was charged into a 5 L reactor containing MeOH (600 mL). Ammonium formate (132.4 g, 2.10 moles) was then charged into the reactor and magnetic agitation commenced. AP14894 (400 g, 1.41 moles) in MeOH (1000 mL) was then charged to the reactor. The reactor was equipped with a nitrogen purge and reflux condenser. The reaction mixture was heated at reflux (55 °C) for 3.5 hours after which time TLC analysis indicated all starting material had been consumed. The reaction mixture was then filtered and the filter cake washed with hot MeOH (1100 mL). The filtrate was then heated to 50 °C and water (2750 mL) added. The resulting solid precipitate was agitated overnight and the solids then collected by filtration, washed with water (1 100 mL), and air dried for 7 hours. The solids were then placed in a vacuum oven at 70 °C for 3 days. Product, AP14895, (344.5 g, 86%) was obtained as an off-white solid: mp 132-134 °C; TLC (EtOAc/hexane, 1 :1) Rf = 0.42; Ή NMR (DMSO- d6, 300 MHz) 9.73 (s, 1H), 7.43 (d, J= 7.8 Hz, 1H), 7.33-7.28 (m, 2H), 7.02 (dd, J= 8.0, 1.9 Hz, 1H), 6.88-6.74 (m, 3H), 3.73 (s, 3H), 3.70 (s, 3H), 3.20 (t, J= 7.4 Hz, 2H), 2.86 (t, J= 7.5 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz) 199.6, 158.0, 149.0, 147.5, 138.5, 134.1, 130.1, 120.5, 119.3, 114.5, 112.9, 1 12.3, 55.9, 55.8, 40.2, 29.6; LRMS (ES+) (M+NH4)+ 304; Anal. Calcd for 017Η18θ4: C, 71.31; H, 6.34. Found: C, 71.28; H, 6.21.
(lc) Step 3. Synthesis of [3[3-(3,4-dimethoxyphenyl)-l-oxopropyI]phenoxy]-acetic acid,l,l- dimethylethyl ester (AP 14896).
Figure imgf000009_0002
acetone
AP14895 AP14896
[178445-83-5] [178445-86-8]
A solution of AP14895 (458 g 1.60 moles) in acetone (4580 mL) was treated with K2C03 (332 g) followed by the dropwise addition of a solution of tert-butyl bromoacetate (258.3 mL, 1.60 moles) in acetone (338 mL) over a 1 hour period. The reaction mixture was heated at reflux for 2 hours and then allowed to stir at room temperature overnight. The reaction mixture was shown to be -50% complete by TLC analysis and so was further heated at reflux for an additional 16 hours. After this time the reaction mixture was filtered, the filtercake washed with hot acetone (600 mL), the filtrate concentrated on a rotary evaporator, and then dissolved in MeOH (2500 mL). The methanolic solution was heated to boil and water (500 mL) added till the solution becomes cloudy. The solution was reheated to boil and allowed to cool to room temperature. The resulting precipitate was filtered, dried under vacuum for 2 hours, washed with hexane (600 mL), and placed in a vacuum oven at 40 °C overnight.
The crude product (439 g) was recrystallized by dissolving in MeOH (2175 mL), heating to reflux, and adding water till a cloudy point was observed. Reheating the solution to boil, followed by slow cooling, results in a precipitate which was filtered, dried under vacuum for 2 hours, and was placed in a vacuum oven at 40 °C overnight. Product, AP14896, (390 g, 75%) was obtained: mp 58-58.5 °C; TLC (EtOAc/hexane, 1 : 1) Rf = 0.65; IR (neat) 2975, 1750, 1685, 1590, 1515, 1445, 1370, 1260, 1235, 1 155, 1080, 1030 cm-i; Ή NMR (CDC¾, 300 MHz) 7.57 (d, J = 7.7 Hz, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.12 (dd, J = 8.0, 2.3 Hz, 1H), 6.82-6.77 (m, 3H), 4.56 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 3.25 (t, J = 7.9 Hz, 2H), 3.00 (t, J = 7.8 Hz, 2H), 1.49 (s, 9H); 13C NMR (CDCI3, 75 MHz) 199.2, 168.0, 158.6, 149.4, 147.9, 138.7, 134.2, 130.1, 121.8, 120.6, 113.6, 1 12.3, 11 1.9, 83.0, 66.1, 56.4, 56.3, 41.1, 30.2, 28.4; LRMS (ES+): (M+NH4)+ 418, (M+Na)+ 423; Anal. Calcd for C23H2806: C, 68.98; H, 7.05. Found: C, 68.85; H, 7.07.
(Id) Step 4. Synthesis of [3[(lR)-3-(3,4-dimethoxyphenyl)-l-hydroxypropyl]phenoxy]-acetic acid (AP20792).
Figure imgf000010_0001
AP14896 3. EtOAc recrystallization AP20792
[178445-86-8] [215169-00-9]
A solution of ketone AP 14896 (200 g, 0.499 moles) in THF (1 1 13 mL) under an atmosphere of nitrogen at -35 °C was treated with (+)-DIP-ChIoride™ (220 g, 0.686 moles). The resulting mixture was allowed to stir at -25 to -35 °C for 6 hours, after which time the mixture was treated with water (260 mL) and concentrated on a rotary evaporator to remove THF. The concentrated mixture was then treated with MeOH (500 mL) followed by a 5N NaOH solution (400 mL) and the reaction stirred for 1 hour.
Concentration of the reaction mixture to remove MeOH afforded an aqueous residue which was adjusted to pH 6 by the addition of a 2N HCl solution and allowed to stir for 16 hours after which time the mixture was washed with EtOAc (3 x 400 mL). The aqueous layer was further adjusted to pH 3 and the resultant precipitated solids stirred for 5 hours, filtered, and triturated with a 1% aqueous citric acid solution (200 mL). The solids were allowed to dry under vacuum for 2 hours and transfered to a vacuum oven and heated at 40 °C overnight to afford product, AP20792, (170 g, 98%) as a colorless solid.
The product was recrystallized in the following manner: AP20792 (341.3 g) was suspended in EtOAc (900 mL) and heated at reflux for 2.5 hours with agitation and filtered while hot. The filtercake was weighed (6 g, -1.8%). The filtrate was reheated to boil for 2 hours then seeded with material of 99.5% ee and the solution allowed to cool to room temperature with agitation. The solids were filtered and placed in a vacuum oven at 40 °C for 2 days to afford product (25 g, 74%) as a colorless solid: mp 125.5-126.5 °C; TLC (AcOH:MeOH:CHCl3> 2:5:93) Rf = 0.22; [a]22 D +6.36 (c = 1.00, DMSO); UV (MeOH) Xmax 284 (ε 2,712, sh), 278 (ε 4,343), 272 (ε 3,907, sh), 219 (ε 14,081, sh) nm; Ή NMR (CD3OD, 300 MHz) 7.02 (t, J = 8.1 Hz, 1 H), 6.74-6.71 (m, 2 H), 6.63-6.48 (m, 4 H), 4.42 (s, 2 H), 4.35 (t, J = 6.0 Hz, 1 H), 3.57 (s, 3 H), 3.56 (s, 3 H), 2.46-2.28 (m, 2 H), 1.85-1.67 (m, 2 H); 13C NMR
(CD3OD, 75 MHz) 171.6, 158.5, 149.3, 147.6, 147.2, 135.3, 129.3, 120.6, 1 19.2, 1 13.3, 1 12.5, 1 12.4, 1 12.2, 73.1, 64.8, 55.5, 55.3, 41.0, 31.5; LRMS (ES+): (M+NH4)+ 364, (M+Na)+ 369; (ES-): M- 345; HRMS (FAB): (M-H)- calcd: 345.1339, meas: 345.1335. Anal. Calcd for C40H48N2O5: C, 65.88; H, 6.40. Found: C, 65.70; H, 6.48. (le) Step 5. Synthesis of AP20793 from compound Y and AP20792.
Figure imgf000011_0001
A stirred suspension of AP20792 (28 g, 0.081 mol), Compound Y»3HC1 salt (see Examples 4 and 5) (9.6 g, 0.040 mol) and HBTU (31 g, 0.040 mol) in DMF (200 mL) was treated with triethylamine (70 mL) at room temperature. The reaction mixture was stirred for 1 hour, quenched with aqueous sodium carbonate, and extracted with AcOEt (3 χ 300 mL). The organic solution was dried overNa2S04, filtered, concentrated, and the crude material chromatographed on silica-gel, flushed with
Figure imgf000011_0002
(100:5 to 20). Evaporation of the volatiles produced the product, AP20793, as a white foam (21 g, 66%). MS(M+1): 788. (If) Step 6. Synthesis of (R/S)-2-(3,4,5-Trimethoxyphenyl)butyric acid (AP14900).
Figure imgf000012_0001
AP17382 AP14900
A 20 L reactor was purged with nitrogen and 3,4,5-trimethoxyphenylacetic acid (1000 g, 4.42 moles) added followed by THF (4000 mL). The suspension was stirred until all acid was dissolved. The resulting solution was then cooled to -25 °C and a 1.0 M THF solution of sodium bis(trimethylsilyl)amide added via cannula over a period of 1 hour in 2 batches of 500 mL each ( 10.0 moles total) and the mixture stirred for a further 30 minutes. The temperature of the reaction mixture was not allowed to rise above - 15 °C during the course of addition. The resulting cream colored colloidal solution was treated at -25 *C with ethyl iodide (424 mL, 5.30 moles) via cannula over a 1 hour period. (A heat kick of ~ 5 °C may be observed for the initial addition of 50 mL of ethyl iodide. If this occurs, the temperature was adjusted to - 25 "C and ethyl iodide addition continued.) The solution was allowed to stir at -25 °C for 2 hours as the colloidal solution slowly changes to a homogeneous brown solution. The brown solution was then allowed to warm to room temperature and stirred overnight. After this time the reaction mixture was quenched, with constant stirring, with water (1500 mL) and allowed to stir for a further 1.5 hours. The organic and aqueous layers were allowed to then separate and the organic layer removed and extracted with water (2 χ 1000 mL). All aqueous solutions were combined and acidified to pH 2 by the addition of a 2N HC1 solution (-3500 mL) and the solution extracted in batches of— 400 mL with an roughly equivalent volume of EtOAc (6000 mL total). The combined organic extracts were washed with brine (2 x 1500 mL) and reduced to a volume of ~ 2000 mL on a rotary evaporator at which time a brown crystalline solid began to precipitate. The solution was allowed to cool and the solid material was filtered, washed with a 1 : 1 EtOAcihexanes solution, and the cream colored solids left in a vacuum oven at 40 °C overnight for a first crop of product, AP14900, (582.8 g). The filtrate was further evaporated and two additional crops (166.2 and 158.1 g) were obtained (907.05 g total, 80.6%).
(lg) Step 7. Synthesis of (S)-2-(3,4,5-Trimethoxyphenyl)butyric acid (AP17360).
Figure imgf000013_0001
AP14900 AP17360
[195202-08-5]
AP14900 (500 g, 1.97 moles) and (-)-cinchonidine (580 g, 1.97 moles) were charged into a 10 L reactor equipped with mechanical agitation. Acetonitrile (7500 mL) was added and the mixture heated to reflux for 30 minutes. The homogeneous solution was allowed to cool to room temperature with concomitant formation of salts. The solids were then filtered and the crystallization procedure was carried out an additional five times utilizing acetonitrile (7000, 7000, 6500, 6500, and 5000 mL) as solvent. The diastereomeric salt was then suspended in water (1400 mL) and dichloromethane (600 mL) and the solution was agitated until all salt was dissolved. The agitated mixture was adjusted to pH 2 by the addition of concentrated HCl, the organic layer was separated and the aqueous layer extracted with a further amount of CH2C12 (2 300 mL). The combined organic layers were then washed with a 1 N HCl solution (2 200 mL) to remove any remaining (-)-cinchonidine. These acid washings were then reextracted with CH2C12 (100 mL) and all CH2C12 solutions were combined. The combined organic solutions were washed with a 10% aqueous NaHC03 solution (200 mL), dried over anhydrous MgS04, concentrated on a rotary evaporator to a volume of -250 mL, and then hexane was added (500 mL). The solution was heated and cooled and an additional portion of hexane (200 mL) was added. The solution was then concentrated on a rotary evaporator until solids appeared and was allowed to sit overnight. The resultant solids were filtered, triturated with hexane (2 300 mL), and placed in a vacuum oven at 50 'C for 84 hours to afford product (105.0 g, 21%) as an off-white solid: [a]22 D +54.8 (c = 1.07, MeOH, 30 min, 99.1% ee material); Ή NMR (DMSO-d6, 300 MHz) 6.34 (s, 2 H), 3.52 (s, 6 H), 3.40 (s, 3 H), 3.11 (t, J = 7.6 Hz, 1 H) 1.76-1.64 (m, 1 H), 1.46-1.36 (m, 1 H), 0.60 (t, J = 7.3 Hz, 3 H); l3C NMR (DMSO- d6, 75 MHz) 175.1, 153.1, 136.9, 135.8, 105.4, 60.3, 56.2, 53.1, 26.7, 12.4. Anal. Calcd for C,3H1805: C, 61.41 ; H, 7.13. Found: C, 61.47; H, 7.20.
(lh) Step 8. Synthesis of [S-(R*,R*)]-l-[l-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-2- piperdinecarboxylic acid (API 7362).
Figure imgf000014_0001
A solution of AP17360 (10.0 g, 0.039 moles) in CH2C12 (100 mL) was treated with methyl-L- pipecolate hydrochloride (7.2 g, 0.04 moles) followed by 2-chloro-l-methylpyridinium iodide (12.77 g, 0.050 moles). The reaction mixture was then treated dropwise with triethylamine (16.66 mL, 0.120 moles) resulting in a 22°C rise in the temperature of the reaction mixture. The solution was allowed to stir for 2 hours, after which time the CH2C12 was removed on a rotary evaporator, the residue (~ 50 mL volume) was dissolved in MeOH (60 mL), and the solution was treated with water (5 mL) followed by lithium hydroxide monohydrate (8.26 g, 0.197 moles). The mixture was stirred overnight then treated with water (20 mL) and the MeOH removed on a rotary evaporator at 40°C. The resulting aqueous solution was treated with EtOAc (60 mL) followed by a saturated aqueous NaHC03 solution (60 mL) and the organic layer washed with water (10 mL). The combined aqueous layers were then acidified to pH 4 by careful addition of a 2N HC1 solution and the resulting suspension cooled to 10 °C. The precipitate was filtered, triturated with a 1% aqueous citric acid solution (100 mL) and air dried under vacuum at 58 °C to provide product, AP17362, (10.5 g, 73%): mp 173.5-174 "C; [ ] 2 D +10.9 (c = 1.01, DMSO, 30 min); UV (MeOH) max 270 (ε 990), 232 (ε 11,161), 207 (ε 49,079) nm; Ή NMR (DMSO- d6, 300 MHz) 6.55 (s, 2 H), 5.13 (d, J = 4.4 Hz, 1 H), 3.85-3.64 (m, 1 1 H), 2.77-2.70 (m, 1 H), 2.12 (d, J = 13.4 Hz, 1 H), 1.99-1.85 (m, 1 H), 1.65-1.55 (m, 4 H), 1.38-1.18 (m, 2 H), 0.84 (t, J = 7.2 Hz, 3 H); Ή NMR (CD3OD, 300 MHz) 6.74 (s, 2 H), 5.43 (d, J = 4.0 Hz, 1 H), 4.13-3.83 (m, 1 1 H), 3.03 (td, J = 13.5, 3.0 Hz, 1 H), 2.44 (d, J = 13.8 Hz, 1 H), 2.24-2.14 (m, 1 H), 1.90-1.40 (m, 6 H) 1.09 (t, J = 7.3 Hz, 3 H); ,3C NMR (DMSO-d6, 75 MHz) 172.9, 172.2, 153.0, 136.2, 105.4, 60.2, 56.2, 56.0, 51.8, 49.4, 43.1, 28.5, 26.8, 25.3, 21.0, 12.8; 13C NMR (CD3OD, 75 MHz) 175.4, 174.5, 154.9, 137.5, 106.8, 61.5, 57.1, 53.9, 52.1, 45.2, 29.9, 28.2, 26.8, 22.3, 13.2; HRMS (FAB): (M-H)- calcd: 364.1760, meas: 364.1774. Anal. Calcd for C,9H2706: C, 62.45; H, 7.45; N, 3.83. Found: C, 62.32; H, 7.61 ; N, 3.88.
(li) Step 9. Synthesis of AP20187 from AP20793 and AP17362.
Figure imgf000015_0001
A mixture of AP20793 (19g, 0.024 mol), API 7362 (19 g, 0.52 mol), and DMAP ( .6 g, 0.046 mol) in CH2C12 (60 mL) was treated with DCC (11 g, 0.053 mol) at 0 °C. The reaction mixture was stirred for 2 hours at 0 °C, and allowed to warm to room temperature with stirring for 48 hours. The mixture was filtered and then chromatographed on silica-gel to give pure product, AP20187, (6 g) and impure fractions (8 g). The yield of the pure product was 21 g, 59%.
(lj) Step 10. Synthesis ofAP20187 mesylate salt.
To a solution of AP20187 (30 g, 0.0202 mol) in AcOEt (150 mL) was added MeS03H ( 1.944 g, 0.0202 mol) in AcOEt (10 mL) at 0 °C over 10 minutes. After stirring at room temperature for 10 minutes, hexane (300 mL) was added and the resulting mixture was stirred at 0 °C for 4 hours. The white solid product was filtered and dried under vacuum (27 g, 85%).
Example 2. Chiral synthesis of (S)-2-(3,4,5-Trimethoxyphenyl)butyric acid (AP17360). A chiral synthesis for AP17360 was developed to reduce the level of diastereomeric impurities present in AP1903 and AP20187.
Figure imgf000015_0002
(3a) Synthesis of compound X.
Figure imgf000016_0001
LiCl (3g, 0.071 moles) was dried in a flask under high vacuum at 150 °C overnight. To this AP22895 (5g, 0.013 moles) pre-dissolved in dry THF (135 mL) was added. The resulting mixture was cooled to -5 °C in an ice/salt bath and to this cooled mixture was added lithium bis(trimethylsilyl)amide (33 mL, 1.0 M in THF 0.033 moles). After stirring for 1 hour, ethyl iodide (5.5 mL 0.017moles) was added dropwise. The reaction mixture was stirred at this temperature for an additional 3 hours. The mixture was then acidified with 2N HC1 and extracted into EtOAc. The organic layer was dried over MgS04 and evaporated to produce a foamy material. The foamy material was taken up in diethylether and triturated with heptanes to furnish pure crystalline compound X (2.5 g).
(3b) Chiral s nthesis of AP17360.
Figure imgf000016_0002
A solution of the amide (0.5 g, 0.0012 mol) in dioxane (6 mL) was slowly added to a cooled (0 °C) solution of 4.5 M ¾S04 (6 mL). When the addition was complete, the mixture was refluxed for 2 hours. The reaction was basified carefully with NaOH to pH 12, and washed with EtOAc twice. The combined organic layer was then dried and evaporated to recover the pseudoephedrine side product as an off white solid (0.17g ca. 85% purity). The aqueous layer was then carefully acidified to pH 3 and extracted with EtOAc. Drying the organic layer over MgS04, filtration, and evaporation of the organic solvent afforded a crude material (0.33g).
Example 4. Synthesis of 2-N,N-dimethylaminomethyl-l ,3-diaminopropane trihydrochloride (compound Y).
The linker 2-N,N-dimethylaminomethyl-l,3-diaminopropane was synthesized for use as an intermediate in the synthesis of AP20187 as outlined in the synthetic scheme below.
Figure imgf000017_0001
j»«**s CIV"", 1)NtN{CHOP OWM*
Figure imgf000017_0002
Synthesis of diethyl 2,2-dimethyl-l,3-dioxan-5,5-dicarboxylate (1).
Figure imgf000017_0003
To a clear solution of diethyl bis(hydroxymethyl)malonate in 478 mL (6.52 mol) of acetone and
478 mL (8.45 mol) of acetone dimethylacetal was added 1.1 mL (42 mmol) of concentrated sulfuric acid and the reaction was stirred at room temperature overnight (19 hours). After 120 mL of saturated sodium carbonate was added, the mixture was stirred at room temperature for 15 minutes. The layers were separated and the semi-crystalline residue was washed with acetone (2 χ 250 mL). The organics were evaporated. The residue was dispersed in 500 mL of ether and 250 mL of saturated Na2C03, and stirred for 20 minutes. After the layers were separated, the organic layer was stirred with 250 mL of brine for 5 minutes and the layers separated. The organic layer was dried, evaporated, and placed under vacuum for 3 hours to produce a colorless oil, 527.5 g, in 94% yield.
(4b) Synthesis of diethyl 2,2-dimethyl-l,3-dioxan-5-carboxylate (2).
Figure imgf000018_0001
i
Potassium hydroxide (15 g, 2.667 mol) was stirred in 1843 mL of anhydrous ethanol and 97 mL of isopropanol to produce a clear solution. To this clear solution was added 1 (527 g, 2.026 mol) in 184 mL of ethanol and 10 mL of isopropanol. The reaction was stirred at room temperature under nitrogen for 5 hours and then evaporated. Water (580 mL) was added and cooled to -4 °C. To this solution was added 58 mL of concentrated HC1 and 1.2 L of 1.0 M HC1 to reach a pH of 2.5 (followed by pH paper). The solution was extracted with ethyl acetate (4 χ 1 L, pH adjusted to 2.5 following each extraction). The combined organics were dried and evaporated to a colorless oil. After the addition of 1.35 L of pyridine, the solution was stirred at 90 °C overnight (16 hours). The solution was distilled at 80 °C (ca. 150 mmHg) to remove the pyridine, and the product was removed by distillation at 55-65 °C (1-2 mmHg), 261.7 g, in 69% yield.
While diethyl bis(hydroxymethyl) malonate was used in step 4(a) to make the diethyl compound that was converted into compound 2, other aliphatic or aromatic malonate esters esters could also be used to generate the analogous aliphatic or aromatic ester of compound 2, which is subsquently converted into an amide and reduced as described below.
(4c) Synthesis of dimethylamino-2,2-dimethyl-l,3-dioxan-5-carboxylate (3).
Figure imgf000018_0002
1 3
A mixture of 2 (210 g, 1.1 16 mol), 3.2 L of dimethylamine (2.0 M in THF, 4.6 mol), and 245 mL of sodium methoxide (25-30% in methanol) was stirred at room temperature under nitrogen overnight. After the addition of 300 g of ice to the flask, the mixture was heated at 40 °C to remove the excess dimethylamine (trapped in a solution of 1.0 M HC1 over 2 hours), and then evaporated to 2/3 of the volume. The two layers were separated and the aqueous layer was extracted with CH2CL2 (2 χ 400 mL). The organics were dried, evaporated, and co-evaporated with THF (2 χ 300 mL) to give a light yellow solid, 170 g, in 81.4% yield. (4d) Synthesis of 5-dimethylamino-2,2-dimethyl-l,3-dioxan (4).
Figure imgf000019_0001
I i
L1ALH4 (37.7 g) was suspended in 1.8 L of anhydrous THF under nitrogen at room temperature and stirred for 5 minutes. To this suspension was then dropped in a solution of 3 (169 g, 0.903 mol) in 1 L of anhydrous THF, keeping the inner temperature lower than 25 °C. The mixture was refluxed for 4 hours. After cooling to room temperature, the reaction was quenched with 600 mL of pre-cooled water, keeping the inner temperature lower than 3 °C. 1.5 L of CH2CL2 was added with stirring. The top clear solution was decanted. The remainder was placed into a separatory funnel, and the clear solution was drained slowly. The solid was washed with CH2CI2 twice. The organics were washed with brine, dried, and evaporated to a light yellow oil, 149 g, in 95% yield.
(4e) Synthesis of 3-bromo-2-bromomethyl-N,N-dimethylpropylamine (5).
Figure imgf000019_0002
Compound 4 (60 g, 0.346 mol) was dissolved in 760 mL of THF and 673 mL of 1.0 M HC1. The reaction was stirred at room temperature overnight to finish the deprotection as judged by NMR. The mixture was evaporated at 55 °C to produce
65 g of oil. To the oil was added 500 mL of 48% HBr and the reaction was stirred at 150 °C overnight (21 hours). After cooling to room temperature, 250 mL of 48% HBr was added and the reaction mixture stirred for another 8 hours at 150 °C. Another 350 mL of 48% HBr was added and the reaction mixture stirred again overnight at 150 °C. The reaction mixture was cooled to room temperature, evaporated, and then co-evaporated with ethanol to produce a dark brown solid, which was refluxed in 650 mL of ethanol, filtered while hot, and cooled to room temperature forming crystals over several days. Filtration gave a light grey solid, 64 g, in 54.4% yield. (4d) Synthesis of 2-N,N-dimethylaminomethyl-l,3-diaminopropane trihydrochloride (compound
Figure imgf000020_0001
The dibromide salt 5 (58.5 g, 0.172 mol) was stirred in 410 mL of water and 540 mL of saturated Na2C03 for 5 minutes and 1 L of CH2C12 was added. After stirring for another 5 minutes, the layers were separated. The aqueous layer was extracted with CH2CI2 (4 χ 600 mL). The organics were dried over Na2C03 twice and evaporated to produce a solid (32 g). The solid was suspended in 1325 mL of anhydrous acetonitrile and sodium diformylamine (24.53 g, 0.258 mol) was added. The reaction was stirred at 100 °C overnight. After cooling to room temperature, the solid was filtered out and the filtrate was evaporated. The residue was dissolved in 630 mL of anhydrous ethanol and HC1 in dioxane (4.0 M, 255 mL, 1.012 mol) was added. The reaction was stirred at 100 °C for 3 hours. After cooling to room temperature, the mixture was filtered. The solid was stirred in 320 mL of anhydrous ethanol overnight, filtered, and dried to give a white solid (compound Y), 21 g, in 51% yield.
Example 5. Synthesis of 2-N,N-dimethyIaminomethyl-l,3-diaminopropane starting from 3- bromo-2-(bromomethyl)proprionic acid.
(5a) Synthesis of N N-dimethyl-3-bromo-2-(bromomethyl) proprionic amide.
Figure imgf000020_0002
3-bromo-2-(bromomethyl)proprionic acid (50 g, 0.20 mol) was treated with SOCl2 (40 mL, excess) at room temperature and the mixture refluxed for 1 hour. The excess SOCI2 was evaporated and the residue dissolved in CH2C12 (200 mL).
To the above solution was added Me2NH (250 mL, 2.0 in methanol) at
-40 °C over 20 minutes. The resulting reaction mixture was allowed to warm to -10 °C and was diluted with HC1 (200 mL, 2.0 M). The mixture was extracted with CH2C12 (2 χ 200 mL) and the combined organic fractions dried, filtered, and evaporated to produce a yellow oil (44 g, 79%).
(5b) Synthesis of 3-bromo-2-bromomethyl-N,N-dimethylpropylamine, quaternary salt form.
Figure imgf000021_0001
To a solution of N,N-dimethyl-3-bromo-2-(bromomethyl) proprionic amide (44 g) in CH2C12 (300 mL) was added DIBAL (450 mL, 1.0 M in toluene) at -40 °C over 30 minutes. The mixture was allowed to warm to -10 °C over 3 hours and the diluted with CH2C12 (1500 mL). The reaction was quenched with a mixture of water (300 mL) and methanol (100 mL) at -10 °C, followed by stirring at a temperature less that 10 °C for 2 hours. The suspension was filtered, dried, and concentrated to ca. 300 mL. The product crystallized upon standing overnight at room temperature. The crystals were separated from the solution and dried (19 g, 66%). MS(M+1): 178. (5c) Synthesis of 2-N,N-dimethylaminomethyl-l,3-diaminopropane trihydrochloride (compound
Y).
*
Figure imgf000021_0002
3-bromo-2-bromomethyl-N,N-dimethylpropylamine, quaternary salt form, was treated using the method described in Example 4d to produce 2-N,N-dimethylaminomethyl-l,3-diaminopropane.
Other Embodiments
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
This application claims benefit of and priority to U.S. Provisional Application No. 61/436,430, filed January 26, 201 1, which is incorporated by reference herein in its entirety. Other embodiments are within the claims. What is claimed is:

Claims

1. The compound
2. The compound
Figure imgf000023_0001
or a salt thereof.
3. The quaternary salt of 3-bromo-2-bromomethyl-N,N-dimethylpropylamine in solid form and described by the formula:
Figure imgf000023_0002
Figure imgf000023_0003
5. A method for the chiral synthesis of the compound, API 7360, the method comprising: (a) reacting the compound AP22895 with ethyl iodide in the presence of a base to form compound X:
Figure imgf000023_0004
and (b) cleaving the compound X under acidic conditions to produce AP I 7360:
Figure imgf000024_0001
6. The method of claim 5 wherein the base is lithium bis(trimethylsilyl)amide.
7. A method for producing dimethyl amide 3 by treating the corresponding ethyl ester with dimethylamine in the presence of base:
Figure imgf000024_0002
to form the desired dimethyl amide.
8. A method for producing compound 4 by providing the corresponding amide 3 and treating it with a reducing agent to produce compound 4:
Figure imgf000024_0003
9. The method of claim 8 in which the reducing agent is L1AIH4.
10. A method for producing 2-N,N-dimethylaminomethyl-l ,3-<naminopropane (compound 6) the method comprising:
Figure imgf000024_0004
6
(a) reacting compound 4 with HBr to form 3-bromo-2-bromomethyl-N,N-dimethylpropylamine; and (b) reacting the 3-bromo-2-bromoraethyl-N,N-dimethylpropylamine with diformylamine to produce 2-N,N-dimethylaminomethyl-l,3-diaminopropane.
1 1. A method for producing 2-N,N-dimethylaminomethyl-l ,3-diaminopropane (compound 6) , the method comprising providing the quaterna :
Figure imgf000025_0001
and reacting it with diformylamine to produce 2-N,N-dimethylaminomethyl-l ,3-diaminopropane. 12. A method for roducing AP20793:
Figure imgf000025_0002
AP20793
the method comprising: (a) dissolving a composition comprising the carboxylic acid, AP20792, of the formula:
Figure imgf000025_0003
in a solvent; (b) treating the resulting solution with a carboxyl activating agent to form activated AP20792; and (c) reacting the activated AP20792 with a composition comprising 2-N,N- dimethylaminomethyl-l,3-diaminopropane to form a mixture comprising AP20793.
13. The method of claim 12 which further comprises the step of producing 2-N,N- dimethylaminomethyl-l ,3-diaminopropane by the method of claim 10.
14. The method of claim 12 which further comprises the step of producing 2-N,N- dimethylaminomethyl-l ,3-diaminopropane by the method of claim 1 1.
15. A method for producing AP20187, having the formula:
Figure imgf000026_0001
the method comprising coupling the dimeric alcohol, AP20793, with the carboxylic acid, AP20792, having the formula:
Figure imgf000026_0002
to yield AP201 87.
16. A method for producing AP20187 by:
(a) coupling 2-N,N-dimethylaminomethyl-l ,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793 ; and
(b) coupling the AP20793 so produced with AP17362 to yield AP20187.
17. A method for producing AP20187 by:
(a) reacting 3-bromo-2-bromomethyl-N,N-dimethylpropylamine or the quaternary salt thereof with diformylamine to produce 2-N,N-dimethylaminomethyl-l ,3-diaminopropane;
(b) coupling 2-N,N-dimethylaminomethyl- l ,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and
(c) coupling the AP20793 so produced with API 7362 to yield AP201 87.
18. The method of claim 16 which further includes the step of producing AP I 7362 by coupling AP I 7360 with methyl-L-pipecolic acid, or a salt thereof.
19. The method of claim 17 which further includes the step of producing AP 1 7362 by coupling AP I 7360 with methyl-L-pipecolic acid, or a salt thereof.
20. The method of any of claims 5 - 19 which further comprises recovering the compound so produced, or a salt thereof, from the reaction mixture.
PCT/US2012/022642 2011-01-26 2012-01-26 Methods and compositions for the synthesis of multimerizing agents WO2012103279A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/981,051 US9024028B2 (en) 2011-01-26 2012-01-26 Methods and compositions for the synthesis of multimerizing agents
AU2012209103A AU2012209103B2 (en) 2011-01-26 2012-01-26 Methods and compositions for the synthesis of multimerizing agents
US14/607,831 US9573934B2 (en) 2011-01-26 2015-01-28 Methods and compositions for the synthesis of multimerizing agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436430P 2011-01-26 2011-01-26
US61/436,430 2011-01-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/981,051 A-371-Of-International US9024028B2 (en) 2011-01-26 2012-01-26 Methods and compositions for the synthesis of multimerizing agents
US14/607,831 Continuation US9573934B2 (en) 2011-01-26 2015-01-28 Methods and compositions for the synthesis of multimerizing agents

Publications (2)

Publication Number Publication Date
WO2012103279A2 true WO2012103279A2 (en) 2012-08-02
WO2012103279A3 WO2012103279A3 (en) 2012-09-20

Family

ID=46581394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022642 WO2012103279A2 (en) 2011-01-26 2012-01-26 Methods and compositions for the synthesis of multimerizing agents

Country Status (3)

Country Link
US (2) US9024028B2 (en)
AU (1) AU2012209103B2 (en)
WO (1) WO2012103279A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126344A1 (en) 2017-12-20 2019-06-27 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6610016B2 (en) * 2015-06-15 2019-11-27 Dic株式会社 Method for producing carbonyl compound using decarboxylation reaction
CN105198796B (en) * 2015-09-22 2017-10-03 上海晋鲁医药科技有限公司 The method of one kind synthesis carboxylic acid of S 1 [(S) 2 (3,4,5 2,4,5-trimethoxyphenyl) bytyry] piperidines 2
CN116425876A (en) 2016-04-01 2023-07-14 凯德药业股份有限公司 BCMA binding molecules and methods of use thereof
CR20180461A (en) 2016-04-01 2019-03-05 Kite Pharma Inc RECEIVERS OF CHEMICAL ANTIGENS AND T-CELLS AND METHODS OF USE
EA201892193A1 (en) 2016-04-01 2019-06-28 Амген Инк. CHEMICAL RECEPTORS TO FLT3 AND METHODS OF THEIR APPLICATION
RS63735B1 (en) 2016-04-01 2022-12-30 Kite Pharma Inc CHIMERIC RECEPTORS AND PROCEDURES OF THEIR USE
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOS CIRCUIT SYSTEMS
JOP20180042A1 (en) 2017-04-24 2019-01-30 Kite Pharma Inc Humanized Antigen-Binding Domains and Methods of Use
US11390655B2 (en) 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
MX2020010753A (en) 2018-04-10 2021-01-29 Amgen Inc Chimeric receptors to dll3 and methods of use thereof.
EP3823993A1 (en) 2018-07-18 2021-05-26 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
CA3177829A1 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
TW202045547A (en) 2019-03-01 2020-12-16 美商艾洛基因醫療公司 Dll3 targeting chimeric antigen receptors and binding agents
CN109734655B (en) * 2019-03-11 2020-06-02 都创(上海)医药科技有限公司 Synthesis process of homodimer of FKBP ligand
KR20220004028A (en) 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 Methods for making allogeneic CAR T cells
WO2020219848A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Rituximab-resistant chimeric antigen receptors and uses thereof
CN111548275A (en) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 Synthetic method of 2- (aminomethyl) -N1, N1-dimethylpropane-1, 3-diamine trihydrochloride
MX2023005491A (en) 2020-11-24 2023-08-09 Lyell Immunopharma Inc METHODS FOR PREPARING REJUVENATED T CELLS, COMPOSITIONS THAT INCLUDE THEM AND METHODS OF USE THEREOF.
US20220227832A1 (en) 2020-12-21 2022-07-21 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4376876A1 (en) 2021-07-26 2024-06-05 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
TW202440623A (en) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580993A (en) * 1993-09-10 1996-12-03 Zambon Group S.P.A. Process for the preparation of iopamidol and 5-amino-2,2-dialkyl-1,3-dioxanes
US6417403B1 (en) * 1998-04-14 2002-07-09 Samsung Fine Chemicals Co., Ltd. Process for preparing chiral (s)-2,3-disubstituted-1-propylamine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150527A (en) * 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580993A (en) * 1993-09-10 1996-12-03 Zambon Group S.P.A. Process for the preparation of iopamidol and 5-amino-2,2-dialkyl-1,3-dioxanes
US6417403B1 (en) * 1998-04-14 2002-07-09 Samsung Fine Chemicals Co., Ltd. Process for preparing chiral (s)-2,3-disubstituted-1-propylamine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNENKOV ET AL.: 'Synthesis of Biomimetic Polyamines.' ARKIVOC vol. XIII, 2009, pages 116 - 130 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126344A1 (en) 2017-12-20 2019-06-27 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives

Also Published As

Publication number Publication date
AU2012209103B2 (en) 2015-12-03
AU2012209103A1 (en) 2013-05-02
US9024028B2 (en) 2015-05-05
US9573934B2 (en) 2017-02-21
US20150148543A1 (en) 2015-05-28
US20140171649A1 (en) 2014-06-19
WO2012103279A3 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
WO2012103279A2 (en) Methods and compositions for the synthesis of multimerizing agents
EP2513114B1 (en) Pyrrolo[2,3-d]pyrimidine compounds
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP6832946B2 (en) How to prepare kinase inhibitors and their intermediates
AU2016213768A1 (en) Chemical process
US20170204065A1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
KR102384529B1 (en) Process for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamide
KR20140009125A (en) Methods and compositions for treatment of diabetes and dyslipidemia
KR102711647B1 (en) A novel tnf activity inhibitor compound and its pharmaceutically acceptable salt
JPH02306947A (en) Preparation of chiral bata-amino acid
WO2020140956A1 (en) Process for preparing sulfonamide compounds
JP6369721B2 (en) Lysophosphatidylserine derivative
KR101134021B1 (en) Manufacturing method of pitavastatin hemicalcium using novel intermediates
DE602005002738T2 (en) SYNTHESIS PROCEDURE AND BENZOXATHYLINDICLE PRODUCTS
CN111556861A (en) Preparation method of jasmonate compound
JP2006257079A (en) Method for producing piperidinone compound and production intermediate
CN111039963A (en) WXFL10203614 water-soluble analogue and synthetic method thereof
KR100468314B1 (en) Intermediate for preparing levosulpiride and preparation method thereof
WO2016146599A1 (en) Method for producing phenylalanine derivatives
JP2014185091A (en) Method of manufacturing 3-amine-4-piperidone derivative
JPH0544465B2 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12738900

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2012209103

Country of ref document: AU

Date of ref document: 20120126

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13981051

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12738900

Country of ref document: EP

Kind code of ref document: A2